Glaucoma Pipeline Analysis Report 2026

Report Coverage

The Glaucoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into glaucoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for glaucoma. The glaucoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The glaucoma pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with glaucoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to glaucoma.

Read more about this report - Request a Free Sample

Glaucoma Pipeline Outlook

Glaucoma is a chronic, progressive eye disease marked by optic nerve damage that disrupts the transmission of visual information to the brain. It most commonly develops due to increased intraocular pressure from impaired aqueous humor outflow, resulting in gradual, irreversible vision loss if not diagnosed and treated early.

Glaucoma treatments aim to reduce intraocular pressure and slow optic nerve damage using prescription eye drops, laser therapy, minimally invasive surgical procedures, or sustained-release drug delivery systems based on disease stage and patient response. In January 2024, the United States Food and Drug Administration approved iDose® TR, a travoprost intracameral implant, marking a significant advancement in the glaucoma drug pipeline by providing continuous intraocular pressure reduction for up to three years, thereby reducing reliance on daily prescription eye drops.

Glaucoma Epidemiology

The glaucoma drug pipeline is increasingly influenced by rising incidence rates and a large undiagnosed patient population. According to the World Health Organization, glaucoma affects nearly 80 million people worldwide and is the second leading cause of blindness. As per projections, about 118 million individuals are expected to be predisposed to glaucoma by 2040, including over 4.5 million cases of blindness. According to global estimates, nearly 50% of affected individuals remain unaware of their condition. Incidence increases with age, affecting over 2% of people above 40 years and more than 4% of those aged 80 years and above. According to the Glaucoma Research Foundation, an estimated 4.22 million adults in the United States had glaucoma in 2022, with prevalence rising significantly among older adults and high-risk demographic groups, supporting sustained demand for innovative pipeline therapies.

Glaucoma – Pipeline Therapeutic Assessment

Glaucoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total glaucoma clinical trials, with a 27% share, reflecting therapies already on the market and driving immediate patient access. Phase II and phase III, each at 24%, indicate promising mid-to-late stage developments likely to expand treatment options soon. Early-phase and Phase I research further foster innovative drug discovery, strengthening long-term market growth.

Glaucoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the glaucoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and peptides. The glaucoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for glaucoma. Novel nitric oxide-donating prostaglandin analogs are emerging in the glaucoma drug pipeline to enhance intraocular pressure reduction. For instance, NCX 470, a small-molecule, nitric oxide-donating bimatoprost eye drop, is in Phase 3 development for open-angle glaucoma and ocular hypertension. In June 2025, Nicox announced that the last patient completed the Denali Phase 3 trial, marking a key milestone toward the United States NDA submission in H1 2026.

Glaucoma Clinical Trials – Key Players

The EMR report for the glaucoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed glaucoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in glaucoma clinical trials:

• Perfuse Therapeutics, Inc.
• Life Biosciences Inc.
• IVIEW Therapeutics Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch & Lomb Incorporated
• AbbVie
• Insight Eyecare Specialties, Inc.
• Amydis Inc.
• PolyActiva Pty Ltd.
• Amneal Pharmaceuticals, LLC
• Alcon

Glaucoma – Emerging Drugs Profile

Key Questions Answered in the Glaucoma Pipeline Insight Report

• Which companies/institutions are leading the glaucoma drug development?
• Which company is leading the glaucoma pipeline development activities?
• What is the current glaucoma commercial assessment?
• What are the opportunities and challenges present in the glaucoma pipeline landscape?
• What is the efficacy and safety profile of glaucoma pipeline drugs?
• Which company is conducting major trials for glaucoma drugs?
• Which companies/institutions are involved in glaucoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in glaucoma?

Reasons To Buy This Report

The Glaucoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for glaucoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into glaucoma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Glaucoma Therapeutics Market

Glaucoma Surgery Devices Market

Glaucoma Epidemiology Forecast